

Confirmation
of the final results of the MabionCD20 NHL clinical trial

In
reference to Current Report No. 6/2018 dated 15 January 2018 and
subsequent current reports regarding initial results of the MabionCD20
clinical trial carried out on patients treated for non-Hodgkin's
lymphomas _NHL_, the Management Board of Mabion S.A. _The "Company"_
hereby informs that on May 25, 2018 an external entity contracted to
analyse the results regarding responses to treatment of RA patients
provided it with a confirmation that the status of results of the
clinical trial reported in the aforementioned reports, after a detailed
verification, has been changed from "initial" to "final".

Hence
the positive assessment of results of the clinical trial remained
unchanged.

The
final versions of reports will be attached to the marketing
authorisation application _MAA_. The Company notes that positive results
of the trial do not guarantee that the product will be approved by the
European Medicines Agency _EMA_.